Eton Pharmaceuticals announced preliminary results from a pilot study of ET-700 for Wilson disease, demonstrating significantly improved gastrointestinal tolerability compared to GALZIN. While ET-700 showed a lower rate of adverse events (8% vs 67% for GALZIN), its copper absorption inhibition was more modest (12% reduction vs 46% for GALZIN), leading the company to plan additional study arms in 2027 for faster-release formulations.
“The tolerability findings are exciting and reinforce our belief that a slower release zinc can improve tolerability, which is a notorious issue with zinc treatment. We are encouraged by the initial results, which showed a benefit over placebo, and our next objective is to improve ET-700’s effect on copper absorption.”
Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals
Eton Pharmaceuticals Research Collaboration with Baylor College of Medicine
Eton Pharmaceuticals has entered into a license and development agreement with Baylor College of Medicine to evaluate mecasermin (ET-900) for the treatment of infantile and epileptic spasms. The partnership includes an investigator-sponsored Phase 2 clinical study with patient dosing targeted for Q1 2027, following the submission of an Investigational New Drug application to the FDA.
Eton Pharmaceuticals Signs $10M M&A Deal with Aquestive Therapeutics, Inc.
Eton Pharmaceuticals acquired exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal film from Aquestive Therapeutics for an upfront fee of $10 million and up to $47.5 million in milestones. The deal includes a 20-year supply agreement and targets the $450 million annual U.S. seizure rescue market with an anticipated launch in April 2027.
Eton Pharmaceuticals has launched IMPAVIDO (miltefosine) capsules in the United States for the treatment of visceral, cutaneous, and mucosal leishmaniasis. The company has integrated the product into its Eton Cares rare disease commercial infrastructure, providing patient support services and centralized distribution through Anovo Specialty Pharmacy.